Venus Medtech launches $331m Hong Kong IPO roadshow
Biotechnology company Venus Medtech (Hangzhou) has kicked off bookbuilding for its Hong Kong listing, eyeing a HK$13bn ($1.66bn) valuation.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: